课题基金 / 基金详情

SMN associated proteins and compounds for SMA therapy

SMN associated proteins and compounds for SMA therapy
用于 SMA 治疗的 SMN 相关蛋白和化合物
批准号:
6639776
负责人:
JIANHUA ZHOU
金额:
$23.26万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-06-01 至 2006-05-31

项目摘要

项目成果

JIANHUA ZHOU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The autosomal recessive spinal muscular atrophy (SMA) is one of the most common genetic causes of infant death. In SMA, there is anterior horn cell death and muscle weakness. Deletions or mutations in the survival motor neuron gene, SMN, are responsible for the disease. There are two SMN genes. However, only telomeric copy (SMNt or SMNI) causes disease. Due to a single nucleotide difference, T in the second gene SMN2 from C in SMNI, the majority of SMN2 mRNA or protein skips exon7, resulting in an unstable SMNA7 protein and reduction of its oligomerization ability. Therefore, the presence of the SMN2 gene in SMA patients can not compensate for the loss of the SMNI gene. To understand the pathogenesis of SMA, the first goal of this proposal is to use the yeast two-hybrid screens to identify SMN interacting proteins, particularly those from motor neurons. The interactions will be further characterized by other complementary methods including mammalian two hybrid assays, in vitro binding assays and in vivo co-immunoprecipitation assays. The biological significance of interactions between SMN and its interactors will be investigated in cell lines, and as long-term goals, in animal models. The second goal of this proposal is to develop cell-based systems for therapeutic studies of SMA based on the hypothesis that increasing of total or full-length SMN protein from SMN2 would reduce the severity of SMA. Stable cell lines and transgenic mice expressing exon 7 splicing cassettes with reporters such as GFP, luciferase or P-lactamase will be established. Both high and low throughput screening (HTS, LTS) will be used to identify small molecules to promote inclusion of exon 7 in SMN2 mRNA and protein. These compounds will be tested in SMA mouse models. Signal pathways and other mechanisms that regulate RNA splicing of SMN genes will be investigated. 1 ZNS1 SRB R(01) 3 1 R01 NS41665-01 DECEMBER 13-14, 2000 ZHOU, DR. JIANHUA
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inhibition of Complement Pathways with VCP As A Treatment For Alzheimer's Disease
  • 批准号:
    10602757
  • 项目类别:
  • 资助金额:
    $49.72万
  • 财政年份:
    2023
  • 负责人:
    JIANHUA ZHOU
  • 依托单位:
Cell Based Assays for Compounds That Regulate Tau Exon 10 Splicing
Targeting Bcl-x splicing for cancer treatment
Targeting Bcl-x splicing for cancer treatment
海外基金